USRE46453EExpiredUtility
Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer
Est. expiryApr 19, 2026(expired)· nominal 20-yr term from priority
A61P 35/00A61P 37/04A61P 31/12A61P 31/20A61P 15/00C07K 2319/33A61K 2039/585C07K 14/475C12N 2710/20034C12N 2710/20023A61K 2039/53C07K 2319/02C12N 7/00C07K 2319/00C07K 14/005A61K 39/12C07K 14/70575C12N 2710/20022C07K 14/025C07K 19/00C12N 15/62
45
PatentIndex Score
0
Cited by
7
References
4
Claims
Abstract
The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing the polynucleotide. The present invention further relates to a pharmaceutical composition comprising the fusion protein or the vector; and a method for treating a disease caused by a human papilloma virus using the pharmaceutical composition.
Claims
exact text as granted — not AI-modifiedThe invention claimed is:
1. A fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus type 16 (HPV16), a signal peptide tPa (tissue plasminogen activator), and an immune enhancing peptide Flt3 (fms-like tyrosine kinase receptor-3) ligand for a subject, wherein the fusion polypeptide of E6 and E7 has the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 14.
2. The fusion protein according to claim 1 , wherein tPa has the amino acid sequence of SEQ ID NO: 2.
3. The fusion protein according to claim 1 , wherein the Flt3 ligand has the amino acid sequence of SEQ ID NO: 16.
4. A pharmaceutical composition for the treatment and prevention of a disease caused by a human papilloma virus in a subject, comprising the fusion protein of claim 1 and a pharmaceutically acceptable carrier.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.